- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06306391
Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.
March 12, 2024 updated by: Parc de Salut Mar
Physiologically Based Pharmacokinetic Modelling of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.
This is a phase I interventional clinical trial and the aim will be to characterize the PK and PD of two formulations of naloxone (intranasal and intravenous) in healthy subjects, which will be used to verify/validate nasal-CNS-PBPK (Physiologically Based Pharmacokinetic) model predictions following intranasal dosing.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ana Maria Aldea Perona, PhD
- Phone Number: (+34) 933160484
- Email: aaldea@researchmar.net
Study Contact Backup
- Name: Rafael De la Torre Fornell, PhD
- Phone Number: (+34) 933160484
- Email: rtorre2@researchmar.net
Study Locations
-
-
-
Barcelona, Spain, 08003
- Recruiting
- IMIM (Hospital del Mar Medical Research Institute)
-
Contact:
- Rafael De la Torre Fornell, PharmD, PhD
- Phone Number: 1780 00343160780
- Email: rtorre@imim.es
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male or female volunteers according to physical examination, vital signs (blood pressure, heart rate and body temperature), ECG and safety laboratory parameters and results should be within normal ranges or considered as non-clinically relevant by the investigator.
- Age ≥ 18 and ≤ 55 years.
- Body mass index (BMI) ≥ 18 and ≤ 30.
- Able/willing to be compliant with the study restrictions.
- Able to read Spanish and adhere to study requirements.
- Signed informed consent prior to any study-mandated procedure.
Exclusion Criteria:
- Life-time substance use disorders (SUD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
- Consumption of prescribed opiates (in the last 6 months).
- Smoking.
- History of or ongoing clinically relevant diseases or conditions.
- Being under any administrative or legal supervision.
- Pregnancy and breastfeeding
- Positive blood or urine test for drugs of abuse or alcohol breath test prior to study drug administration.
- Life-time history of mental diseases.
- History of anxiety or depression not completely recovered within 12 months prior to study drug administration, as assessed by the Dual Diagnosis Screening Interview (DDSI).
- Any other clinically relevant disease or condition that in the judgment of the investigator might interfere with the subject's ability to comply with study procedures or requirements and/or bias the interpretation of the study results and/or jeopardize the subject's safety.
- Ongoing gastrointestinal diseases or history of gastrointestinal surgery affecting absorption.
- Subjects with a clinically significant disease within one month prior to study drug administration.
- Any clinically relevant findings in physical examination, vital signs, 12-lead ECG and safety laboratory parameters.
- Positive hepatitis or HIV test.
- Known hypersensitivity to any drug or drug excipients.
- Use of drugs known to induce or inhibit hepatic drug metabolism (e.g., cimetidine) within one month prior to study administration or during the study and use of citrus juice during the study.
- Any prescription or over-the-counter (OTC) product including herbal, homeopathic, vitamins, minerals and nutritional supplements within one week prior to study drug administration.
- Intake of foods or beverages containing xanthine (more than 5 units of coffee, tea or cola drinks per day).
- Donation of blood or plasma within one month prior to study drug administration or transfusion of blood or plasma for medical/surgical reasons or intention to donate blood or plasma within one month after study drug administration.
- History of inadequate venous access and/or experience of difficulty donating blood.
- Subject included in a clinical study within 3 months prior to study drug administration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous naloxone
|
Nyoxid 1.8 mg nasal spray, solution in single-dose container.
Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -> washout period ->intravenous (n=4) and Intravenous ->washout period -> intranasal (n=4).
|
Experimental: Intranasal naloxone
|
Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution).
Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -> washout period ->intravenous (n=4) and Intravenous ->washout period -> intranasal (n=4).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effects of naloxone on heart rate (HR).
Time Frame: Up to 24 hours.
|
Up to 24 hours.
|
Effects of naloxone on systolic and diastolic blood pressure (BP).
Time Frame: Up to 24 hours.
|
Up to 24 hours.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effects of naloxone on plasma cortisol at visit 1 and visit 4.
Time Frame: Up to 24 hours.
|
Up to 24 hours.
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse effects.
Time Frame: Up to 24 hours.
|
Up to 24 hours.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 5, 2024
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
March 5, 2024
First Submitted That Met QC Criteria
March 5, 2024
First Posted (Actual)
March 12, 2024
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMIMFCTL/NLX_1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Intravenous naloxone
-
Norwegian University of Science and TechnologySt. Olavs Hospital; University of IcelandCompleted
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Smerud Medical Research International AS; A/S Den norske...Completed
-
INSYS Therapeutics IncCompleted
-
Dartmouth-Hitchcock Medical CenterCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedOpioid-Related DisordersUnited States
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Isfahan University of Medical SciencesCompletedMorphinan Opioid OverdoseIran, Islamic Republic of
-
Massachusetts General HospitalUnknownSurgery | Pain, Acute | Opioid-use Disorder
-
S.L.A. Pharma AGCompletedChronic Pain | Opioid Induced ConstipationGermany, United Kingdom